Literature DB >> 12829440

Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration.

Robert F Schwabe1, Ramon Bataller, David A Brenner.   

Abstract

Activated hepatic stellate cells (HSCs) are the main producers of extracellular matrix in the fibrotic liver and are involved in the regulation of hepatic inflammation. The aim of this study was to characterize the role of regulated on activation, normal T-cell expressed, and presumably secreted (RANTES) in activated HSCs. RANTES mRNA and protein secretion were strongly induced after stimulating HSCs with TNF-alpha, IL-1beta, or CD40L. RANTES production was NF-kappaB dependent, because inhibitor-kappaB (IkappaB) superrepressor and dominant-negative IkappaB kinase-2 almost completely blocked RANTES expression. NF-kappaB activation was sufficient to drive RANTES expression as demonstrated by the strong induction of RANTES in HSCs expressing NF-kappaB-inducing kinase. The JNK/activator protein-1 pathway also contributed to RANTES expression as demonstrated by the blocking effects of the JNK inhibitor SP600125. HSCs responded to stimulation with recombinant human (rh)RANTES with an increase in intracellular calcium concentration and a rapid increase in free radical formation. Furthermore, rhRANTES induced ERK phosphorylation, ERK-dependent [3H]thymidine incorporation, and HSC proliferation. Additionally, rhRANTES induced focal adhesion kinase phosphorylation and a substantial increase in HSC migration. HSCs functionally expressed chemokine receptor-5 (CCR5), as shown by flow-cytometric analysis and RT-PCR, and the inhibitory effects of a blocking CCR5 antibody on rhRANTES-induced ERK activation, proliferation, and migration. Diphenylene iodonium and N-acetylcysteine inhibited rhRANTES-induced ERK activation and HSC proliferation, indicating that NADPH oxidase-dependent production of reactive oxygen species was required. In conclusion, RANTES and CCR5 represent potential mediators of 1) HSC migration and proliferation and 2) a cross-talk between HSCs and leukocytes during fibrogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829440     DOI: 10.1152/ajpgi.00215.2003

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  97 in total

1.  Macrophage migration inhibitory factor is required for recruitment of scar-associated macrophages during liver fibrosis.

Authors:  Mark A Barnes; Megan R McMullen; Sanjoy Roychowdhury; Nabil Z Madhun; Kathryn Niese; Mitchell A Olman; Abram B Stavitsky; Richard Bucala; Laura E Nagy
Journal:  J Leukoc Biol       Date:  2014-11-14       Impact factor: 4.962

Review 2.  Functional role of chemokines in liver disease models.

Authors:  Hacer Sahin; Christian Trautwein; Hermann E Wasmuth
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-26       Impact factor: 46.802

Review 3.  Mechanisms of hepatic fibrogenesis.

Authors:  Ursula E Lee; Scott L Friedman
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

4.  Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice.

Authors:  Marie-Luise Berres; Rory R Koenen; Anna Rueland; Mirko Moreno Zaldivar; Daniel Heinrichs; Hacer Sahin; Petra Schmitz; Konrad L Streetz; Thomas Berg; Nikolaus Gassler; Ralf Weiskirchen; Amanda Proudfoot; Christian Weber; Christian Trautwein; Hermann E Wasmuth
Journal:  J Clin Invest       Date:  2010-10-18       Impact factor: 14.808

Review 5.  Role of the tissue microenvironment as a therapeutic target in hepatocellular carcinoma.

Authors:  Bhavna Rani; Yuan Cao; Andrea Malfettone; Ciprian Tomuleasa; Isabel Fabregat; Gianluigi Giannelli
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 6.  Extracellular matrix and liver disease.

Authors:  Elena Arriazu; Marina Ruiz de Galarreta; Francisco Javier Cubero; Marta Varela-Rey; María Pilar Pérez de Obanos; Tung Ming Leung; Aritz Lopategi; Aitor Benedicto; Ioana Abraham-Enachescu; Natalia Nieto
Journal:  Antioxid Redox Signal       Date:  2014-01-08       Impact factor: 8.401

7.  CCR1 and CCR5 promote hepatic fibrosis in mice.

Authors:  Ekihiro Seki; Samuele De Minicis; Geum-Youn Gwak; Johannes Kluwe; Sayaka Inokuchi; Christina A Bursill; Josep M Llovet; David A Brenner; Robert F Schwabe
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

8.  CCR2 promotes hepatic fibrosis in mice.

Authors:  Ekihiro Seki; Samuele de Minicis; Sayaka Inokuchi; Kojiro Taura; Katsumi Miyai; Nico van Rooijen; Robert F Schwabe; David A Brenner
Journal:  Hepatology       Date:  2009-07       Impact factor: 17.425

9.  Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition.

Authors:  Johannes Kluwe; Jean-Philippe Pradere; Geum-Youn Gwak; Ali Mencin; Samuele De Minicis; Christoph H Osterreicher; Jordi Colmenero; Ramon Bataller; Robert F Schwabe
Journal:  Gastroenterology       Date:  2009-09-24       Impact factor: 22.682

10.  Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis.

Authors:  Henning W Zimmermann; Sebastian Seidler; Jacob Nattermann; Nikolaus Gassler; Claus Hellerbrand; Alma Zernecke; Jens J W Tischendorf; Tom Luedde; Ralf Weiskirchen; Christian Trautwein; Frank Tacke
Journal:  PLoS One       Date:  2010-06-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.